Alcobra Pharmaceuticals was founded in 2008 in Tel Aviv, Israel. The company has grown since then, establishing offices in the US and building a strong IP portfolio. Alcobra focuses on developing innovative, best-in-class drug candidates to treat Attention Deficit Hyperactivity Disorder (ADHD), Fragile X Syndrome and other cognitive disorders.
